The Supreme Court on Thursday handed down a unanimous decision authored by Justice Ketanji Brown Jackson, with all nine justices joining her opinion in a closely watched pharmaceutical patent dispute.
The justices ruled 9-0 in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., reversing a lower court decision and sending the case back for further proceedings, marking a rare moment of full agreement on a court often portrayed as ideologically divided. Jackson, a Biden appointee, has been one of the court’s most frequent dissenters, making her authorship of a unanimous opinion all the more notable.
The decision clarified the legal standard for when claims that generic drugmakers encouraged patent infringement can proceed when they market medicines with so-called “skinny labels,” which exclude patented uses—a shift that may affect how lower-cost drugs are brought to market.
The ruling extends beyond the courtroom: The case could influence how quickly cheaper generic drugs reach the market and how companies describe their products’ risks. Legal standards like the one clarified in the ruling can shape both drug prices and the volume of lawsuits tied to widely used medications. Generic drugs account for the vast majority of prescriptions in the United States, and drugmakers warned that a decision favoring Amarin could have discouraged cheaper alternatives, potentially driving up prices.
Why It Matters
The decision highlights a reality frequently overlooked in public discourse: The Supreme Court still decides a significant share of its cases unanimously. While high-profile rulings often break 6–3 along ideological lines, data shows that unanimous decisions remain a substantial portion of the court’s output in recent terms.
It also underscores Jackson’s evolving role on the court. She was in the majority, according to Supreme Court term statistics, in about 72 percent of cases during the court’s 2024–25 term—the lowest of any justice.
What to Know
- The case: The dispute centered on whether a generic drugmaker can still face liability for inducing patent infringement after using a “skinny label” that omits patented uses of a branded drug.
- Background: Amarin, the maker of the drug Vascepa, sued Hikma, which sought to market a generic version while carving out a patented cardiovascular use from its label.
- Lower courts: A federal district court dismissed the case, but the U.S. Court of Appeals for the Federal Circuit allowed it to proceed, finding the allegations plausible.
- The ruling: The Supreme Court reversed that decision 9–0 in an opinion written by Jackson, clarifying the legal standard governing when such claims can proceed.
- Broader context: The case is part of an ongoing effort by the court to clarify how patent law applies to generic drugs under the Hatch-Waxman Act, which governs competition between brand-name and generic pharmaceuticals.
The ruling is not Jackson’s first unanimous opinion this term. She also authored a 9-0 decision earlier this year in Urias‑Orellana v. Bondi, an immigration case requiring federal appeals courts to defer to immigration judges’ findings when reviewing asylum claims, reinforcing a highly deferential standard in deportation cases. In that case, involving a Salvadoran family seeking protection in the United States, Jackson wrote that courts must uphold agency determinations unless the evidence clearly compels a different conclusion, a decision seen as strengthening executive authority in immigration enforcement.
The unanimous ruling also contrasts with cases in which Jackson has sharply broken from her colleagues. In Fernandez v. United States, decided last week, she issued a lone dissent in an 8-1 ruling, separating not only from the court’s conservative majority but also from fellow liberal justices Elena Kagan and Sonia Sotomayor. The case centered on whether prisoners can use compassionate release to challenge their convictions, and Jackson argued the majority took too narrow a view of that pathway for relief.
Why Vascepa Matters
Vascepa is a prescription drug derived from fish oil that is used to reduce triglyceride levels and lower the risk of heart attack, stroke, and other cardiovascular events in high-risk patients. It was first approved in 2012 to treat severe hypertriglyceridemia—dangerously high levels of fats in the blood—but later gained approval for a broader use: reducing cardiovascular risk in a much larger group of patients.
That second use significantly expanded the drug’s commercial potential and became the focus of Amarin’s patent protections. While generic manufacturers were free to compete for the older indication, the newer cardiovascular use remained protected—setting up the legal conflict at the center of the case.
What Is a ‘Skinny Label’ in Generic Drug Cases?
The case turns on a regulatory concept known as a “skinny label,” which allows generic drugmakers to bring lower-cost versions of medicines to market even when some uses remain under patent. Because drugs are often approved for multiple conditions over time, each use can be protected by a different patent. When one use is no longer protected, a generic manufacturer can ask regulators for approval to market the drug only for that unpatented use, carving the rest out of its label.
The legal question in this case involved “induced infringement”—whether Hikma’s broader marketing language effectively encouraged doctors to prescribe the generic drug for uses that were still under patent, even though those uses were not listed on the label. Amarin argued that referring to the drug as a “generic version” of Vascepa and citing its overall market could blur that distinction. The Supreme Court rejected that argument, finding those actions did not amount to what Jackson described as “active encouragement” of infringement.
What Happens Next
The case now returns to the lower courts, where judges will apply the Supreme Court’s clarified legal framework to determine whether Amarin’s claims can proceed under the proper standard.
The decision clarifies the legal standard for when generic drugmakers can face liability in marketing products approved under “skinny label” pathways. It may also reduce litigation risks associated with bringing those lower-cost alternatives to market.
Timely competition from generic drugs is “the single most important mechanism for lowering prescription drug spending in the U.S.,” according to a 2026 analysis in the medical journal JAMA.
More broadly, the ruling is likely to shape how pharmaceutical companies navigate the line between patent protection and competition—and how quickly cheaper medications reach patients.
